Pnu282987
PNU282987 is a chemical compound used in various research applications. It is a selective agonist of the alpha7 nicotinic acetylcholine receptor (α7 nAChR). The product is designed for use in in vitro studies and assays exploring the role of the α7 nAChR in cellular and biological processes.
Lab products found in correlation
10 protocols using pnu282987
Sourcing of Nicotine and Cotinine Analogs
Cell Line Characterization and Culture
Neurotransmitter Regulation of NGF Signaling
Acetylcholine Signaling Pathway Assay
Stock solutions were prepared in water (ACh, pervanadate) or in DMSO (PNU-282987, PP2, SU6656).
Pharmacological Evaluation of PNU-282987
Electrophysiological Analysis of α7 nAChR
Neuroinflammation Inhibition Assay
A CCK-8 kit, DMEM-H medium, Penicillin/Streptomycin Solution, and PBS buffer were purchased from Sangon Biotech (Shanghai, China). FBS was purchased from Procell (Wuhan, China). A FastPure Cell/Tissue Total RNA Isolation Kit, HiScript II Q Select RT SuperMix for qPCR (+gDNA wiper), 2 × Taq Plus Master Mix Ⅱ, and ChamQ Universal SYBR qPCR Master Mix were obtained from Vazyme (Nanjing, China). A TNF-α ELISA kit, IL-6 ELISA kit, and IL-1β ELISA kit were purchased from Thermo Scientific (Waltham, MA, USA).
Investigating α7 nAChR Agonist PNU 282987 Effects
Nicotine and α7-nAChR Agonist Effects
Pharmacological administration protocols for cognitive studies
Risperidone (Sigma, UK) was dissolved in a minimum volume of acetic acid, made up to volume with distilled water and pH adjusted to 6 with 0.1M NaOH. Risperidone was administered in a volume of 1 ml/kg via the i.p. route. PNU-282987 (Tocris, UK) was dissolved in isotonic water and given in a volume of 1 ml/kg via the sub-cutaneous (s.c.) route. RJR-2403 oxalate (Tocris, UK) was dissolved in 0.9% saline and given in a volume of 1 ml/kg via the s.c. route. All drug doses were calculated as base equivalent weight and were administered 30 min before the acquisition trial, with the exception of PNU-282987 which was administered 60 min before the acquisition trial. In experiment 3 all drugs were given 30 min before the retention trial, except PNU-282987 which was administered 60 min before the retention trial.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!